1) RSI will cut above its moving average soon but i will take position early because i applied 2 DEMA on prices(which are 5 period (red one) and 20 period (green one)).
2) When 2 DEMA cross each other i will take position a little bit early.
3) CCI cut above its moving average as you see but resistance line of CCI has not been broken yet. But next week it will be...
Look at the flat top breakout triangle forming on the MRNS chart! Classic structure and even better yet; Price target consensus of $30 among wall street analysts!
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken,...
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken,...
Potential near-term catalysts:
- breakthrough therapy designation in RSE
- end-of-PhII meetings for PPD and RSE
- partnership or acquisition
Thesis summary:
Drug showed 100% seizure control at 24h in PhII trial in patients with drug-resistant, life-threatening seizures (RSE)
Intravenous formulation of the drug showed strong anti-depressant activity but oral...
"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with...
The price action has been quite positive in the stock of NASDAQ:MRNS in 2019 gaining almost 65% from the oversold lows in December. Like all Pharmaceutical companies, trails results can move the stock incredibly fast, speculation and rumor has it that the stock is due for a considerable breakout WITH PLENTY OF UPSIDE POTENTIAL. A alert for a break above the...
top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial.
globenewswire.com
MRNS broke its triangle closing to the upside on 9/19. This would be a great time to enter for a swing trade going long.
My Entry $7.91
Target price $9.44
Price of Marinus reacted at an important level. This is a good sign.
My opinion is that Wave 5 UP has just started and will push the stock to much higher levels.
More conservative investors could buy above $7 in order to have a full confirmation of the new up move.
Note: I am Long Marinus and I will increase my position.
It is a promising company in its sector.
MARINUS is a leader in the development of neurosteroids for the treatment of depression. It is developing ganaxolone for PPD (Postpartum Depression).
Topline data from a Phase 2 study should be available in H2.
The stock price dropped after its Q earnings results. Its cash of $21.47M is solid to fund its operations and this is good for me.
Technically the recent...
